Target Price | $32.00 |
Price | $6.48 |
Potential |
393.83%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target Vir Biotechnology Inc 2026 .
The average Vir Biotechnology Inc target price is $32.00.
This is
393.83%
register free of charge
$110.00
1,597.53%
register free of charge
$14.00
116.05%
register free of charge
|
|
A rating was issued by 9 analysts: 7 Analysts recommend Vir Biotechnology Inc to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Vir Biotechnology Inc stock has an average upside potential 2026 of
393.83%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 74.21 | 27.41 |
13.89% | 63.06% | |
EBITDA Margin | -685.70% | -1,910.67% |
7.89% | 178.64% | |
Net Margin | -706.85% | -1,751.21% |
3.10% | 147.75% |
8 Analysts have issued a sales forecast Vir Biotechnology Inc 2025 . The average Vir Biotechnology Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Vir Biotechnology Inc EBITDA forecast 2025. The average Vir Biotechnology Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Vir Biotechnology Inc Analysts have issued a net profit forecast 2025. The average Vir Biotechnology Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.83 | -3.51 |
16.56% | 8.36% | |
P/E | negative | |
EV/Sales | 0.80 |
6 Analysts have issued a Vir Biotechnology Inc forecast for earnings per share. The average Vir Biotechnology Inc EPS is
This results in the following potential growth metrics and future valuations:
Vir Biotechnology Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Barclays |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Needham |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 31 2025 |
Leerink Partners |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Jan 09 2025 |
Analyst Rating | Date |
---|---|
Locked
Barclays:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
Needham:
Locked
➜
Locked
|
Feb 27 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 31 2025 |
Locked
Leerink Partners:
Locked
➜
Locked
|
Jan 13 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 10 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Jan 09 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.